- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A health professional said Disclosure UK wrongly showed Amgen support. Panel found no breach for 2015 (cause unclear) but breaches for 2016–2017…
Anonymous Roche employees alleged misconduct at a European meeting and excessive call-rate targets. The Panel found no evidence of Code breaches and…
Roche was ruled in breach after Xenical was effectively supplied via a non-HCP at a private clinic and a proposed £55,000 clinic…
PMCPA case AUTH/2354/9/10 (Anonymous v Consilient Health) about promotion of oral contraceptives. The matter was ruled outwith the scope of the ABPI…
Anonymous complaint alleged two new Chiesi field staff visited customers before completing validation/training. Panel found no evidence of promotion before sign-off and…
A nurse specialist alleged a Ferring representative harassed staff for appointments and misused a patient telemedicine voicemail. The Panel found the complaint…
PMCPA case AUTH/2891/11/16 (Ex-employee v Astellas). The case was completed 19 Jan 2017. Outcome: No breach; matter was outwith the scope of…
An ex-employee complaint upheld: a Maudsley-based “traffic light” tolerability table and a diabetes/CHD cost-savings chart were found misleading and disparaging. Breaches of…
Anonymous pharmacist alleged off-licence CKD promotion of Invokana at a diabetes conference. Panel couldn’t prove what was said (no breach), but ruled…
A UK-circulated press release about investigational ASTX727 made unsubstantiated benefit/safety claims and implied an incorrect indication for decitabine. Breaches: 3.1, 3.2, 7.9,…
Two online press releases about investigational ASTX727 were circulated to UK outlets. Panel found misleading, unsubstantiated study claims and failure to maintain…
Anonymous group alleged a third-party therapy review provider’s internal email showed commercial bias and disguised promotion in Amgen-funded osteoporosis reviews. Panel and…
A BMJ-hosted ad described Takhzyro as “a new preventative treatment”. PMCPA ruled Takhzyro had been promoted from 1 April 2019, so “new”…
A UK health professional alleged RoActemra prescribing information in a Guidelines in Practice product review was out of date vs SPC updates.…
A patient-organisation congress website listed Daiichi-Sankyo symposia agendas naming Lixiana, Nilemdo and Nustendi with indications but omitted mandatory prescribing/AE/black triangle info and…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.